Pegfilgrastim

Drug Profile

Pegfilgrastim

Alternative Names: Filgrastim SD01; G-Lasta; KRN125; Neulasta; Neulastim; PEG filgrastim; PEG G-CSF; PEG-rmetHuG-CSF; Pegylated filgrastim; R 1471; r-metHuG-CSF-SD-01; SD-01; SD/01

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kyowa Hakko Kirin
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neutropenia; Radiation injuries

Most Recent Events

  • 01 Nov 2015 Launched for Radiation injuries in USA (SC)
  • 01 Nov 2015 Registered for Radiation injuries in USA (SC)
  • 11 Mar 2015 Launched for Neutropenia in Taiwan, South Korea and Vietnam prior to March 2015 (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top